US Patent Issued to BEIJING TIDE PHARMACEUTICAL on Sept. 9 for "Compound for inhibiting and inducing degradation of EGFR kinase" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 10 -- United States Patent no. 12,410,192, issued on Sept. 9, was assigned to BEIJING TIDE PHARMACEUTICAL Co. LTD. (Beijing).

"Compound for inhibiting and inducing degradation of EGFR kinase" was invented by Yanping Zhao (Beijing), Hongjun Wang (Beijing), Yeming Wang (Beijing), Yuanyuan Jiang (Beijing), Futian Fan (Beijing), Huining Liang (Beijing), Xiaoqian Wang (Beijing), Yong Xie (Beijing), Yanhao Zhang (Beijing) and Xuelian Liu (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is an EGFR kinase inhibitor according to general formula (I) and a pharmaceutical composition containing the inhibitor. The invention can be used to treat diseases related to EGFR kinase, such ...